Osteogenic Growth Peptide (10-14) (Synonyms: OGP(10-14); Historphin) |
Catalog No.GA23328
One-Click Copy Product Info
|
Osteogenic Growth Peptide (10-14)은 활성 성장 촉진 펩타이드(OGP)의 절단된 펜타펩티드 단편으로서 Src 키나제(Src) 억제제이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 105250-85-9
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Osteogenic Growth Peptide (10-14)은 활성 성장 촉진 펩타이드(OGP)의 절단된 펜타펩티드 단편으로서 Src 키나제(Src) 억제제이다. Osteogenic Growth Peptide(10-14)은 OGP 수용체에 결합해서 Gi 단백질-MAP 키나제 신호 전달경로를 활성화시킨다[3]. Osteogenic Growth Peptide(10-14)은 강력한 유사분열 촉진제이자 뼈 형성 및 조혈 촉진제로서 골다공증과 치주염 치료에 활용될 수 있다[4].
체외 실험에서 Osteogenic Growth Peptide(10-14)(0.01, 0.1, 1, 10, 100 nM; 1, 5, 7일)을 인간 치주인대 줄기세포(hPDLSCs)에 처리한 결과는 저농도(0.01, 0.1, 1 nM)에서는 세포 증식 및 성골 분화 잠능이 현저하게 증가하였고10 및 100 nM 농도에서는 관련 반응이 나타나지 않았다[5]. Osteogenic Growth Peptide(10-14)(0.1 nM; 7–21일) 처리는 골수 유래 중간엽줄기세포(MSCs)의 성골 분화를 현저하게 촉진하고 지방세포 형성을 억제하고 알칼리 인산분해효소(ALP) 활성 및 광물화 결절 형성을 증가시켰다. 게다가 성골세포 특이적 전사인자 cbfa1의 mRNA 발현을 자극하고 지방세포 특이적 과산화물소체 증식인자 γ-2(PPARγ2)의 mRNA 발현을 억제하였다[6].
체내 실험에서 Osteogenic Growth Peptide(10-14)(1nmol/kg/일; 35일간; 피하 주사)는 대조 시작 30일 전 난소절제(OVX)를 받은 암컷 쥐의 뼈 손실을 현저하게 완화하고 쥐의 성골세포 수를 증가시켰다[7].
References:
[1] Chen YC, et al. Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP(10-14). J Med Chem. 2002;45(8):1624-1632.
[2] Battolla B, et al. The small peptide OGP(10-14) reduces proliferation and induces differentiation of TPO-primed M07-e cells through RhoA/TGFbeta1/SFK pathway. Med Sci Monit. 2011;17(1):SC1-SC5.
[3] Chen Z, et al. Regulation of endochondral ossification by osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)]. Protein Pept Lett. 2009;16(9):1074-1080.
[4] Fazzi R, et al. Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice. Leuk Res. 2002;26(1)
[5] Purbantoro S D, Osathanon T, Nantavisai S, et al. Osteogenic growth peptide enhances osteogenic differentiation of human periodontal ligament stem cells[J]. Heliyon, 2022, 8(7).
[6] Chen ZX, Chang M, Peng YL, et al. Osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)] acts on rat bone marrow mesenchymal stem cells to promote differentiation to osteoblasts and to inhibit differentiation to adipocytes. Regul Pept. 2007;142(1-2):16-23.
[7] Bab I, Chorev M. Osteogenic growth peptide: from concept to drug design[J]. Peptide Science: Original Research on Biomolecules, 2002, 66(1): 33-48.
| 세포 실험 [1]: | |
세포 라인 | 인간의 치주인대줄기세포 (hPDLSCs) |
제조 방법 | 세포는 10% 태아소혈청(FBS), 1% 항생-항진균제 및 1% GlutaMAX가 첨가된 DMEM으로 37 °C, 5% CO₂에서 유지하였습니다. 배지는 48시간마다 교체하였고 융합률 80%에서 전대하였습니다. Osteogenic Growth Peptide(10-14) 처리 할 때 0.01, 0.1, 1, 10, 100 nM 농도를 배지에 보충해서 hPDLSCs를 배양하였습니다. 처리 1, 5, 7일 후 calcein-AM과 요오드화 프로필(PI)로 살아 있는 세포와 죽은 세포를 각각 염색해서 대조 그룹과 처리 그룹을 비교하였습니다. 세포는 24-웰 배양판에 5×10³ 세포/음으로 접종하였고 Carl Zeiss™ Apotome.2 장착 형광 현미경으로 염색 결과를 관찰및 평가하였습니다. |
반응 조건 | 0.01, 0.1, 1, 10 및 100nM; 1, 5 및 7 일 동안 |
응용 분야 | 저농도(0.01, 0.1, 1 nM)의 Osteogenic Growth Peptide(10-14)는 세포 증식을 현저하게 촉진하였지만 10 및 100 nM 농도에서는 관련 효과가 관찰되지 않았습니다. |
References: | |
| Cas No. | 105250-85-9 | SDF | |
| Synonyms | OGP(10-14); Historphin | ||
| Formula | C24H29N5O7 | M.Wt | 499.52 |
| Solubility | DMSO : 8.93 mg/mL (17.88 mM; ultrasonic and warming and heat to 60°C) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0019 mL | 10.0096 mL | 20.0192 mL |
| 5 mM | 400.4 μL | 2.0019 mL | 4.0038 mL |
| 10 mM | 200.2 μL | 1.001 mL | 2.0019 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)